Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer.
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) detains a dismal prognosis and has a limited number of prognostic factors. Inflammation has been demonstrated to play a key role both in PDAC initiation and progression and several inflammation-based prognostic scores have been investigated in a wide range of malignancies. We compared the most analyzed inflammation-based prognostic scores in order to establish their potential impact on prediction of the outcome in advanced PDAC patients. METHODS: A total of 234 advanced PDAC patients undergoing first-line chemotherapy in our institute were retrospectively analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using Kaplan-Meier method and survival differences were evaluated using the log-rank test. Level of statistical significance P was set at 0.05. Only those variables that proved to be associated with statistically significant differences in outcome were compared in multivariate analysis using multiple Cox regression, as to identify their independent role and their relative power against each other. RESULTS: In the whole cohort, median overall survival (OS) was 8.7 months (95% CI: 7.8-9.4 months), median progression-free survival (PFS) was 3.8 months (95% CI: 3.1-4.2 months). At univariate analysis high systemic immune-inflammation index (SII) was related to shorter OS [hazard ratio (HR) =2.04, 95% CI: 1.59-4.19, P=0.0001] and PFS (HR =1.52, 95% CI: 1.11-2.20, P=0.01). This was maintained at multivariate analysis both for OS (HR =2.11, 95% CI: 1.29-3.46, P=0.003) and PFS (HR =1.64, 95% CI: 1.14-2.37, P=0.008), whereas other inflammation-based scores lost their independent role. Elevated SII (≥1,200) was associated with low albumin levels (P=0.03) and with elevated lactate dehydrogenase (LDH) (P=0.01). CONCLUSIONS: Elevated SII represents an independent negative prognostic factor above all others for both OS and PFS in advanced PDAC patients treated with first-line chemotherapy, thus confirming a pivotal role of systemic inflammation on PDAC progression and on patient outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SII, SIRI, MHR, NHR, LHR, and PHR are considered cost-effective and simple laboratory parameters indicating systemic inflammation in many diseases (18, 19, 21–23, 26, 27, 30–34).”
From Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have found that the SII has an important role in predicting the prognosis of patients with some physical diseases, such as tumors, cerebral infarction, cardiovascular disease, and acute pancreatitis (18, 20, 21, 36).”
From Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder (2022) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526 · cited 1×
“…patients treated with gemcitabine and nab-paclitaxel, 10 patients presented high SII value ( ≥ 1,200) and these Chemotherapy regimen Folfirinox 46 [20] Gemcitabine plus nab-paclitaxel 52 [22] Gemcitabine 65 [28] Gemcitabine plus cisplatin or oxaliplatin 41 [18] Other (irinotecan, capecitabine,…”
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579 · cited 2×
“On top of that, its incidence is increasing worldwide in both men and women (1).”
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · cited 1×
“Chemotherapy regimens based on fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel showed antitumor activity with an improvement in survival (3,4).”
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 1×
“Chemotherapy regimens based on fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel showed antitumor activity with an improvement in survival (3,4).”
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502 · cited 1×
“The inclusion criteria consisted of: (I) Age >18 years old; (II) Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤3; (III) Histologically or cytologically confirmed diagnosis of PDAC; (IV) Locally advanced not resectable or metastatic PDAC according to the 8th edition of the American Joint Committee…”
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · cited 1×
“More recently, poly (ADP-ribose) polymerases (PARPs) inhibitor olaparib was demonstrated to be effective as maintenance treatment option in germline BRCA1/2 mutated metastatic PDAC patients who had not progressed during first-line platinum-based chemotherapy (5).”
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269 · cited 1×
“Nevertheless, mortality rate is high, and the 5-year survival rate still stands at 9% (6).”
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ducreux, M., Cuhna, A. S., Caramella, C., Hollebecque, A., Burtin, P., Goéré, D., Seufferlein, T., Haustermans, K., Van Laethem, J. L., Conroy, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv295 · Cited by 1,300 · cited 1×
“There is a deep link between PDAC and inflammation: both hereditary and sporadic chronic pancreatitis increase by 10 times the risk of developing PDAC (21,22).”
Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., Templeton, A. J., & Früh, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.024 · Cited by 986
Optimizing the outcomes of pancreatic cancer surgery
Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0112-1 · Cited by 943 · cited 1×
“PDAC is mostly diagnosed at advanced stage and surgery, which is the only potentially curative approach, is feasible only in 15–20% of patients (2).”
Ray-Coquard, I., Cropet, C., Van Glabbeke, M., Sebban, C., Le Cesne, A., Judson, I., Tredan, O., Verweij, J., Biron, P., Labidi, I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3845 · Cited by 784 · cited 1×
“It has been demonstrated that lymphopenia is related to shorter survival and lower response to treatment in several malignancies, including pancreatic cancer, representing the immune system inability of contrasting tumor progression (47).”
Qi, Q., Zhuang, L., Shen, Y., Geng, Y., Yu, S., Chen, H., Liu, L., Meng, Z., Wang, P., & Chen, Z. (2016) · Cancer · doi:10.1002/cncr.30057 · Cited by 761 · cited 1×
“In this study we compared several immune and nutritional scores (NLR, PLR, LMR, ALI, SIRI, SII, PNI), extensively investigated in other cancers, including PDAC (24-27) and we documented the value of SII in prediction of patient outcome.”
Role of platelets and platelet receptors in cancer metastasis
Schlesinger, M. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0669-2 · Cited by 690 · cited 1×
“Recent studies have also demonstrated how platelets impact positively on cancer cells proliferation, stimulating mitogenic pathways (37).”
The Platelet Lifeline to Cancer: Challenges and Opportunities
Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V., & Sood, A. K. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.002 · Cited by 638 · cited 1×
“Moreover, many studies have underlined that thrombocytosis and neutrophilia are related to cancer evolution and worse clinical outcome, also in PDAC (31-34).”
HIF‐1 at the crossroads of hypoxia, inflammation, and cancer
Balamurugan, K. (2016) · International Journal of Cancer · doi:10.1002/ijc.29519 · Cited by 572 · cited 1×
“Cancer cells hypoxia adaptation is mediated by hypoxia-inducible factor 1 (HIF-1) and preclinical studies have demonstrated how HIF-1 may enhance systemic inflammation status (51).”
Platelets guide the formation of early metastatic niches
Labelle, M., Begum, S., & Hynes, R. O. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411082111 · Cited by 555 · cited 1×
“…exhibit ligands of endothelium cells receptors [P-selectin, intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)], improving endothelial activation, cancer cells extravasation (40) and, therefore, leading to the formation of early metastatic niches (41).”
Labelle, M., & Hynes, R. O. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0329 · Cited by 486 · cited 1×
“…exhibit ligands of endothelium cells receptors [P-selectin, intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)], improving endothelial activation, cancer cells extravasation (40) and, therefore, leading to the formation of early metastatic niches (41).”
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
(2011) · New England Journal of Medicine · doi:10.1056/nejmc1107627 · Cited by 428
Neutrophils in Cancer: Two Sides of the Same Coin
Uribe-Querol, E., & Rosales, C. (2015) · Journal of Immunology Research · doi:10.1155/2015/983698 · Cited by 422 · cited 1×
“It seems that cancer cells are able to produce cytokines such as granulocyte colony-stimulating factor (G-CSF) and IL-6, leading to an increased neutrophil count in patient blood (45).”
Pinato, D. J., North, B. V., & Sharma, R. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.92 · Cited by 421 · cited 2×
“Similarly, in other malignancies the systemic inflammation response index (SIRI), the advanced lung cancer inflammation index (ALI) (16) and the prognostic nutritional index (PNI) were documented to play a significant role in predicting patient outcome (17,18).”
Jafri, S. H., Shi, R., & Mills, G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-158 · Cited by 389 · cited 1×
“In this study we compared several immune and nutritional scores (NLR, PLR, LMR, ALI, SIRI, SII, PNI), extensively investigated in other cancers, including PDAC (24-27) and we documented the value of SII in prediction of patient outcome.”
Immunosuppression associated with chronic inflammation in the tumor microenvironment
Wang, D., & DuBois, R. N. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv123 · Cited by 355 · cited 1×
“It has been amply demonstrated that chronic inflammation generates an immunosuppressive and tumor-promoting microenvironment by the accumulation of pro-inflammatory cytokines and immune suppressor cells infiltration, promoting tumour initiation, progression and metastasis (30).”
Inflammation and the development of pancreatic cancer
Farrow, B., & Evers, B. M. (2002) · Surgical Oncology · doi:10.1016/s0960-7404(02)00015-4 · Cited by 338
Tumor-Associated Neutrophils in Cancer: Going Pro
Wu, L., Saxena, S., Awaji, M., & Singh, R. K. (2019) · Cancers · doi:10.3390/cancers11040564 · Cited by 337 · cited 1×
“In addition, neutrophils promote CTCs endothelium adhesion and extravasation, and therefore, metastasis initiation (46).”
Xu, X. R., Yousef, G. M., & Ni, H. (2018) · Blood · doi:10.1182/blood-2017-05-743187 · Cited by 325 · cited 1×
“Increasing evidences have shown the crosstalk between cancer cells and platelets, and the concept of tumour cell-induced platelet aggregation has been developed since late 19th century (35).”
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
Mann, D., Edwards, R., Ho, S., Lau, W., & Glazer, G. (2000) · European Journal of Surgical Oncology (EJSO) · doi:10.1053/ejso.1999.0925 · Cited by 294 · cited 1×
“Translational research on this topic is still ongoing. carbohydrate antigen 19-9 (CA19-9) is often increased in advanced PDAC stages and its changes during treatment may be useful in predicting response and progression to current treatment (7-9).”
Looi, C.-K., Chung, F. F.-L., Leong, C.-O., Wong, S.-F., Rosli, R., & Mai, C.-W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 202 · cited 1×
“Early trials have been already developed to test target therapies against inflammatory targets and immune tumor microenvironment (52).”
Paraneoplastic thrombocytosis: the secrets of tumor self-promotion
Lin, R. J., Afshar-Kharghan, V., & Schafer, A. I. (2014) · Blood · doi:10.1182/blood-2014-03-562538 · Cited by 188 · cited 1×
“Cancer cells, by secreting thrombopoietic cytokine such as interleukin-1 (IL-1), interleukin-3 (IL-3) and interleukin-6 (IL-6) are the main cause of hepatic thrombopoietin secretion and thrombocytosis (36).”
Geng, Y., Zhu, D., Wu, C., Wu, J., Wang, Q., Li, R., Jiang, J., & Wu, C. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.10.002 · Cited by 180 · cited 1×
“Similarly, in other malignancies the systemic inflammation response index (SIRI), the advanced lung cancer inflammation index (ALI) (16) and the prognostic nutritional index (PNI) were documented to play a significant role in predicting patient outcome (17,18).”
Jomrich, G., Gruber, E. S., Winkler, D., Hollenstein, M., Gnant, M., Sahora, K., & Schindl, M. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-019-04187-z · Cited by 166 · cited 1×
“Jomrich et al. (48) analyzed the prognostic role of NRL, PLR and SII in a cohort of patients affected by PDAC who underwent surgical resection.”
Ward, Y., Lake, R., Faraji, F., Sperger, J., Martin, P., Gilliard, C., Ku, K. P., Rodems, T., Niles, D., Tillman, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.092 · Cited by 164
Zhou, Y., Wei, Q., Fan, J., Cheng, S., Ding, W., & Hua, Z. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.024 · Cited by 163 · cited 10×
“In addition, we considered NLR, PLR and lymphocyte-to-monocyte ratio (LMR).”
InfluentialNever Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment
Heeke, S., Mograbi, B., Alix‐Panabières, C., & Hofman, P. M. (2019) · Cells · doi:10.3390/cells8070714 · Cited by 146 · cited 1×
“Platelets may adhere at the surface of CTCs, protecting them from immune cells surveillance and promoting cancer cell survival (42).”
Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer
Zhang, K., Hua, Y., Wang, D., Chen, L., Wu, C., Chen, Z., Liu, L., & Chen, H. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1782-x · Cited by 126 · cited 2×
“Inflammation-based prognostic scores mostly studied in PDAC are neutrophil-to-lymphocyte ratio (NLR) (13), platelet-to-lymphocyte ratio (PLR) (14) and recently also the systemic immune-inflammation index (SII), composed by the combination of neutrophils, platelets and lymphocytes (15).”
Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma
Reni, M., Cereda, S., Balzano, G., Passoni, P., Rognone, A., Fugazza, C., Mazza, E., Zerbi, A., Di Carlo, V., & Villa, E. (2009) · Cancer · doi:10.1002/cncr.24302 · Cited by 125 · cited 1×
“In addition, we confirmed the prognostic role of high baseline concentration of tumor marker CA19-9 (28,29).”
Pancreatic cancer microenvironment: a current dilemma
Uzunparmak, B., & Şahin, İ. H. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0221-1 · Cited by 105 · cited 1×
“Serum LDH is an indicator of tumor hypoxia and it is known that PDAC, marked by an abundant desmoplastic stroma and low blood supply, induce hypoxic stress in cancer cells, facilitating tumor progression and worse patients’ outcome and response to chemotherapy (50).”
Inflammation and pancreatic cancer: An updated review
Shadhu, K., & Xi, C. (2018) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_390_18 · Cited by 102 · cited 1×
“Indeed, both immune cells and cytokines are involved in early pancreatic carcinogenesis and, furthermore, in cancer cells invasion, migration and metastasis (12).”
Yu, S.-L., Xu, L.-T., Qi, Q., Geng, Y., Chen, H., Meng, Z.-Q., Wang, P., & Chen, Z. (2017) · Scientific Reports · doi:10.1038/srep45194 · Cited by 100 · cited 1×
“Focusing on LDH, an interesting work by Yu et al. (49) investigated the link between serum level of LDH and systemic inflammation markers such as NRL, PLR and LRM in advanced PDAC patients after gemcitabine-based treatment.”
Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer
Bottsford-Miller, J., Choi, H.-J., Dalton, H. J., Stone, R. L., Cho, M. S., Haemmerle, M., Nick, A. M., Pradeep, S., Zand, B., Previs, R. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0870 · Cited by 96 · cited 1×
“It has been observed in experimental models that decreasing plasmatic platelets concentration the tumor burden decrease and cancer cells chemo-sensibility increase (38).”
He, X., Zhou, T., Yang, Y., Hong, S., Zhan, J., Hu, Z., Fang, W., Qin, T., Ma, Y., Zhao, Y., et al. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.03.005 · Cited by 88 · cited 7×
“Similarly, in other malignancies the systemic inflammation response index (SIRI), the advanced lung cancer inflammation index (ALI) (16) and the prognostic nutritional index (PNI) were documented to play a significant role in predicting patient outcome (17,18).”
InfluentialRelationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency
Parra‐Robert, M., Molina, V., CANIS, S. M., Filella, X., Fradera, J., & PORTO, R. M. (2018) · Anticancer Research · doi:10.21873/anticanres.12931 · Cited by 84 · cited 1×
“carbohydrate antigen 19-9 (CA19-9) is often increased in advanced PDAC stages and its changes during treatment may be useful in predicting response and progression to current treatment (7-9).”
Zhou, Y., Cheng, S., Fathy, A. H., Qian, H., & Zhao, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s154162 · Cited by 82 · cited 8×
“In addition, we considered NLR, PLR and lymphocyte-to-monocyte ratio (LMR).”
InfluentialThrombocytosis as a prognostic marker in gastrointestinal cancers
Voutsadakis, I. A. (2014) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v6.i2.34 · Cited by 73 · cited 1×
“Moreover, many studies have underlined that thrombocytosis and neutrophilia are related to cancer evolution and worse clinical outcome, also in PDAC (31-34).”
Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis
Baumgart, S., Ellenrieder, V., & Fernández-Zapico, M. E. (2011) · Gut · doi:10.1136/gutjnl-2011-301008 · Cited by 69 · cited 1×
“Inflammation has been documented to play a key role in PDAC initiation (11).”
Schernberg, A., Nivet, A., Dhermain, F. G., Ammari, S., Escande, A., Pallud, J., Louvel, G., & Deutsch, É. (2018) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2018.04.002 · Cited by 49 · cited 1×
“It has been widely demonstrated that increased concentration of circulating neutrophils is a predictor of worse outcome in advance cancer patients (43,44).”
Relationship between serum CA19-9 and CEA levels and prognosis of pancreatic cancer.
Wu, L., Huang, P., Wang, F., Li, D., Xie, E., Zhang, Y., & Pan, S. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.11.17 · Cited by 45 · cited 9×
“Translational research on this topic is still ongoing. carbohydrate antigen 19-9 (CA19-9) is often increased in advanced PDAC stages and its changes during treatment may be useful in predicting response and progression to current treatment (7-9).”
InfluentialSignificance of the inflammation-based prognostic score in recurrent pancreatic cancer
Nakagawa, K., Sho, M., Akahori, T., Nagai, M., Nakamura, K., Takagi, T., Tanaka, T., Nishiofuku, H., Ohbayashi, C., Kichikawa, K., et al. (2019) · Pancreatology · doi:10.1016/j.pan.2019.05.461 · Cited by 30 · cited 1×
“In this study we compared several immune and nutritional scores (NLR, PLR, LMR, ALI, SIRI, SII, PNI), extensively investigated in other cancers, including PDAC (24-27) and we documented the value of SII in prediction of patient outcome.”
Takahashi, R., Mabuchi, S., Kuroda, H., Kozasa, K., Yokoi, E., Matsumoto, Y., & Kimura, T. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001019 · Cited by 26 · cited 1×
“Moreover, many studies have underlined that thrombocytosis and neutrophilia are related to cancer evolution and worse clinical outcome, also in PDAC (31-34).”
Lee, S. P., Sung, I., Kim, J. H., Lee, S., Park, H. S., & Shim, C. S. (2019) · Korean Journal of Family Medicine · doi:10.4082/kjfm.18.0057 · Cited by 25
Holub, K., & Conill, C. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02113-y · Cited by 16 · cited 1×
“Moreover, many studies have underlined that thrombocytosis and neutrophilia are related to cancer evolution and worse clinical outcome, also in PDAC (31-34).”
Zhao, W., Wang, P., Jia, H., Chen, M., Gu, X., Liu, M., Zhang, Z., Cheng, W., & Wu, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.16469 · Cited by 11 · cited 1×
“It has been widely demonstrated that increased concentration of circulating neutrophils is a predictor of worse outcome in advance cancer patients (43,44).”
Bittoni, A., Pellei, C., Lanese, A., Giampieri, R., D’Angelo, A., Giglio, E., Cantini, L., Meletani, T., Baleani, M. G., & Berardi, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.08.34 · Cited by 7
Self-citationBittoni, A., Pellei, C., Lanese, A., et al. (2018) · Translational Cancer Research · doi:10.21037/24022 · Cited by 5 · cited 1×
“Translational research on this topic is still ongoing. carbohydrate antigen 19-9 (CA19-9) is often increased in advanced PDAC stages and its changes during treatment may be useful in predicting response and progression to current treatment (7-9).”
Self-citation
Research works printed but not linked: 1
- [22]Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system (4th edition). WHO-IARC, Lyon, 2010.
Cited by
Wei, Y., Wang, T., Li, G., Feng, J., Deng, L., Xu, H., Yin, L., Ma, J., Chen, D., & Chen, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.941728 · Cited by 99
Shui, Y., Li, M., Su, J., Chen, M., Gu, X., & Guo, W. (2021) · Aging · doi:10.18632/aging.203449 · Cited by 57
“The 11 cohort studies were conducted in China (n=4) [12, 14, 15, 17, 18], the Netherlands (n=2) [10], Austria (n=1) [11], Italy (n=1) [16], and the United States of America (USA) (n=1) [13].”
BackgroundJin, M., Yuan, S., Yuan, Y., & Yi, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.735803 · Cited by 54
Mao, L., Li, Z., Wang, Z., Yue, C., Hu, W., & Lü, H. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00785-x · Cited by 53
“For CSS/DFS/PFS, five studies [9, 11, 12, 14, 15] were included in the meta-analysis.”
BackgroundMethodInfluentialWang, S., Wan, Y., & Zhang, W. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s451466 · Cited by 33
Metadata
- Authors
- Bittoni, A., Pecci, F., Mentrasti, G., Crocetti, S., Lupi, A., Lanese, A., Pellei, C., Ciotti, C., Cantini, L., Giampieri, R., Lenci, E., Giglio, E., Bini, F., Copparoni, C., Meletani, T., Baleani, M. G., & Berardi, R.
- Affiliations
- Marche Polytechnic University (IT)
- Corresponding author
- Bittoni, Alessandro
- Pecci, Federica
- ORCID
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2021-02
- Volume
- 9
- Issue
- 3
- Pages
- 251-251
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- PMC
- PMC7940927
- OpenAlex
- W3121703177
- Cited by
- 42
- References
- 52
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 10 · 2023: 13 · 2022: 7 · 2021: 2
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- systemic immune-inflammation index, pancreatic ductal adenocarcinoma, inflammation-based prognostic scores, prognostic factors, overall survival, progression-free survival, first-line chemotherapy, albumin, lactate dehydrogenase, advanced pancreatic cancer, prognostic score comparison, prognostic score validation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.